Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Squamous NSCLC Clinical Trial

Official title: A Randomized, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Sintilimab (IBI308) in Combination With Gemcitabine and Platinum-Based Chemotherapy vs. Placebo in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Treatment for Patients With Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) (ORIENT-12)

Status Completed

Clinical Trial Summary

Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC

Clinical Trial Description

The anti-tumor activity of anti-PD-1 therapy in previously untreated Chinese squamous NSCLC patients will be investigated in this clinical trial. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Squamous NSCLC

• NCT number: NCT03629925
• Study type: Interventional
• Source: Innovent Biologics (Suzhou) Co. Ltd.
• Status: Completed
• Phase: Phase 3
• Start date: September 28, 2018
• Completion date: September 30, 2021